Back to Screener

Healthcare

DocGo Inc.(DCGO)

Live Price

Offline

$0.4635

-8.13% today

1Y Change

-67.65%

Window

Jun 25, 2025 โ†’ Jun 18, 2026

Market Cap
$70.00M
Revenue Growth
-47.7%
EPS Growth
-1020.0%
Dividend Yield
0.0%

Coverage: 247 bars ยท Jun 25, 2025 โ†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

DocGo Inc. (DCGO) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $0.46 and down 67.7% across the available one-year price window (Jun 25, 2025 โ†’ Jun 18, 2026). Baseline metrics include revenue growth of -47.7%, EPS growth of -1020.0%, a dividend yield of 0.0%. What stands out right now is revenue -47.7%, EPS -1020.0%, free cash flow -58.1% with operating margin -32.9% and ROIC -66.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DCGO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

DCGO vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

DCGO

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

DCGO Max Drawdown

-69.94%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for DCGO and SPY.

Calendar-year return history is still loading or unavailable.

Financial profile

DocGo Inc. (DCGO)

Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.

FY Revenue

$318.7M

-27.6% YoY

FY Net Income

$23.7M

-31.3% YoY

Free Cash Flow

-$8.6M

-136.8% YoY

Revenue Growth

-47.7%

EPS Growth

-1020.0%

Gross Margin

30.7%

Net Margin

-56.6%

Income statement

USD

Annual
Metric20252024202320222021
Revenue322M617M624M441M319M
Gross Profit83M214M195M155M110M
Operating Income-89M29M15M22M15M
EBITDA-73M46M31M32M28M
Net Income-182M20M7M35M24M
EPS (Diluted)โ€”โ€”โ€”โ€”โ€”

Balance sheet

USD

Point-in-time
Metric20252024202320222021
Cash & Equivalents52484.8B89M59M157M176M
Total Assets217103.0B456M490M393M310M
Total Liabilities91231.7B140M185M114M83M
Shareholder Equity144011.8B321M301M273M220M
Total Debt29M57M46M20M17M
Net Debt-52484.7B-32M-13M-137M-159M

Cash flow positioning

Latest Full Year

Operating Cash Flow

2M

-106.7% YoY

Capital Expenditures

7M

-21.1% YoY

Free Cash Flow

9M

-136.8% YoY

Key ratios

  • Gross Margin

    30.7%

  • Operating Margin

    -32.9%

  • Net Margin

    -56.6%

  • ROE

    -71.4%

  • Debt / Equity

    0.20x

Next Step

Turn financials into a decision

Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.